Randomized trial demonstrates superior glycemic control and weight reduction with semaglutide over exenatide ER in type 2 diabetes, highlighting its therapeutic value.
Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
No takes yet. Share an insight, caveat, or question.
Ahmann et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: